1.Sales and profit
See section β- Zura Bio Ltd lost $68.7M in fiscal 2025.
Zura Bio Ltd
ZURA Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2022βFY2025
- Today
- 19.9%
- Previous close
- $3.56
- Market cap
- $541M
- P/E
- β
- Day range
-
$3.41 $4.33
- 52-week range
-
$3.36 $7.04
Last close Β· Oct 27, 2026
$4.27
+$0.34 (+8.65%) past year
KIRAβs summary AI analyst
Hi! I read Zura Bio Ltdβs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$64.9M in fiscal 2025, β of revenue.
- In the last 12 months, insiders bought $12.5M of shares on the open market and sold none.
Zura Bio Ltd in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$68.7M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$541M
Oct 27 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$1.13 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
Revenue
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Zura Bio Ltd lost $68.7M in fiscal 2025.
Net income
FY22
Net income β$25.7M
FY23
Net income β$60.4M
FY24
Net income β$52.4M
FY25
Net income β$68.7M
Net income
Q3 '23
Net income β$8.3M
Q4 '23
Net income β$8.5M
Q1 '24
Net income β$7.7M
Q2 '24
Net income β$10.3M
Q3 '24
Net income β$20.7M
Q4 '24
Net income β$13.6M
Q1 '25
Net income β$17.4M
Q2 '25
Net income β$16.0M
Q3 '25
Net income β$18.0M
Q4 '25
Net income β$17.2M
Q1 '26
Net income β$24.2M
Q2 '26
Net income β$26.3M
Diluted EPS
FY22
Diluted EPS β
FY23
Diluted EPS β$2.09
FY24
Diluted EPS β$0.60
FY25
Diluted EPS β$1.06
Diluted EPS
Q3 '23
Diluted EPS β$0.18
Q4 '23
Diluted EPS $2.16
Q1 '24
Diluted EPS β$0.02
Q2 '24
Diluted EPS β$0.17
Q3 '24
Diluted EPS β$0.26
Q4 '24
Diluted EPS β$0.15
Q1 '25
Diluted EPS β$0.19
Q2 '25
Diluted EPS β$0.17
Q3 '25
Diluted EPS β$0.21
Q4 '25
Diluted EPS β$0.49
Q1 '26
Diluted EPS β$0.22
Q2 '26
Diluted EPS β$0.21
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was β$64.9M in fiscal 2025, β of revenue.
Free cash flow
FY22
Free cash flow β
FY23
Free cash flow β
FY24
Free cash flow β$28.2M
FY25
Free cash flow β$64.9M
Free cash flow
Q3 '23
Free cash flow β
Q4 '23
Free cash flow β
Q1 '24
Free cash flow β$5.0M
Q2 '24
Free cash flow β$6.6M
Q3 '24
Free cash flow β$5.7M
Q4 '24
Free cash flow β$10.9M
Q1 '25
Free cash flow β$11.1M
Q2 '25
Free cash flow $11.1M
Q3 '25
Free cash flow β$42.6M
Q4 '25
Free cash flow β$22.3M
Q1 '26
Free cash flow β$18.9M
Q2 '26
Free cash flow $18.9M
Cash from operations vs capital spending
FY22
Cash from operations β$1.1M
Capital spending β
FY23
Cash from operations β$15.1M
Capital spending β
FY24
Cash from operations β$28.1M
Capital spending $0.1M
FY25
Cash from operations β$64.8M
Capital spending $0.1M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$2.6M
Capital spending β
Q4 '23
Cash from operations β$4.1M
Capital spending β
Q1 '24
Cash from operations β$5.0M
Capital spending $0.0M
Q2 '24
Cash from operations β$6.6M
Capital spending $0.0M
Q3 '24
Cash from operations β$5.7M
Capital spending $0.0M
Q4 '24
Cash from operations β$10.8M
Capital spending $0.0M
Q1 '25
Cash from operations β$11.1M
Capital spending $0.0M
Q2 '25
Cash from operations $11.0M
Capital spending β$0.0M
Q3 '25
Cash from operations β$42.5M
Capital spending $0.1M
Q4 '25
Cash from operations β$22.3M
Capital spending $0.0M
Q1 '26
Cash from operations β$18.9M
Capital spending $0.0M
Q2 '26
Cash from operations $18.9M
Capital spending β$0.0M
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY22
Diluted shares β
FY23
Diluted shares 0.03B
FY24
Diluted shares 0.08B
FY25
Diluted shares 0.09B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $12.5M of shares on the open market and sold none.
Bought, 12 months
$12.5M
1 insider
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Access Industries Holdings LLC10% owner | Bought | 2,000,000 | $6.25 | $12.5M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Zura Bio Ltd can carry it.
Cash vs debt (incl. leases)
FY22
Cash $0.0M
Debt β
FY23
Cash $99.8M
Debt β
FY24
Cash $176M
Debt β
FY25
Cash $109M
Debt β
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.0M | $99.8M | $176M | $109M |
| Current ratio | 0.1x | 5.0x | 9.2x | 9.1x |
| Quick ratio | 0.1x | 5.0x | 9.2x | 9.1x |
| Total assets | $5.3M | $101M | $180M | $114M |
| Total liabilities | $14.8M | $21.3M | $19.5M | $12.4M |
| Shareholders' equity | β$32.1M | $59.3M | $147M | $102M |
| Net debt (β = net cash) | β | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY22
Return on capital β
Return on equity β
Return on assets β488.4%
FY23
Return on capital β
Return on equity β442.6%
Return on assets β113.8%
FY24
Return on capital β
Return on equity β50.8%
Return on assets β37.4%
FY25
Return on capital β
Return on equity β55.3%
Return on assets β46.8%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 5 | β / 6 | β / 6 |
| Accruals ratio | β468.1% | β85.4% | β17.4% | β2.6% |
| Altman Z'' | β41.81 | 0.65 | 8.82 | 3.48 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
4 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | β | $44.0M | $24.4M | $42.1M |
| Operating income | β$2.7M | β$62.6M | β$55.2M | β$75.2M |
| Pretax income | β | β$60.6M | β$52.4M | β$68.7M |
| Income tax | β | $0.0M | $0.0M | β |
| Net income | β$25.7M | β$60.4M | β$52.4M | β$68.7M |
| Net income to common | β | β$69.2M | β$45.4M | β$99.4M |
| Diluted EPS | β | β$2.09 | β$0.60 | β$1.06 |
| Diluted shares | β | 0.03B | 0.08B | 0.09B |
| Cash flow | ||||
| Cash from operations | β$1.1M | β$15.1M | β$28.1M | β$64.8M |
| Capital expenditure | β | β | $0.1M | $0.1M |
| Free cash flow | β | β | β$28.2M | β$64.9M |
| Depreciation and amortization | β | β | $0.0M | $0.0M |
| Stock-based compensation | β | $7.5M | $16.8M | $12.3M |
| Balance sheet | ||||
| Cash and short-term investments | $0.0M | $99.8M | $176M | $109M |
| Current assets | $1.8M | $101M | $179M | $112M |
| Current liabilities | $14.8M | $20.3M | $19.5M | $12.4M |
| Property and equipment, net | β | β | $0.1M | $0.1M |
| Total assets | $5.3M | $101M | $180M | $114M |
| Total liabilities | $14.8M | $21.3M | $19.5M | $12.4M |
| Shareholders' equity | β$32.1M | $59.3M | $147M | $102M |
| Returns | ||||
| Return on capital employed | 28.0% | β77.8% | β34.5% | β74.1% |
| Return on equity | β | β442.6% | β50.8% | β55.3% |
| Return on assets | β488.4% | β113.8% | β37.4% | β46.8% |
| Return on tangible equity | β | β116.7% | β30.9% | β97.8% |
| Growth | ||||
| Share count change | β | β | 127.0% | 25.4% |
| Financial health | ||||
| Current ratio | 0.1x | 5.0x | 9.2x | 9.1x |
| Quick ratio | 0.1x | 5.0x | 9.2x | 9.1x |
| Quality scores | ||||
| Altman Z'' | β41.8 | 0.6 | 8.8 | 3.5 |
| Accruals ratio | β468.1% | β85.4% | β17.4% | β2.6% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001855644). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.